MCID: CRC006
MIFTS: 62

Carcinoid Syndrome

Categories: Cancer diseases, Endocrine diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Carcinoid Syndrome

MalaCards integrated aliases for Carcinoid Syndrome:

Name: Carcinoid Syndrome 54 17
Carcinoid Tumor 54 30 17 74
Carcinoid Tumor No Icd-O Subtype 74
Malignant Carcinoid Syndrome 74
Carcinoid Tumor Syndrome 54
Carcinoid Tumors 44

Classifications:



Summaries for Carcinoid Syndrome

NIH Rare Diseases : 54 Carcinoid syndrome refers to a group of symptoms that are associated with carcinoid tumors (rare, slow-growing tumors that occur most frequently in the gastroinestinal tract or lungs). Affected people may experience skin flushing, abdominal pain, diarrhea, difficulty breathing, rapid heart rate, low blood pressure, skin lesions on the face (telangiectasias), and wheezing. In later stages, carcinoid syndrome may damage the heart valves, resulting in symptoms of congestive heart failure. The condition occurs when the carcinoid tumor secretes serotonin or other chemicals into the bloodstream. Only 10% of people with carcinoid tumors develop carcinoid syndrome; most have advanced stage carcinoid tumors that have spread to the liver. Treatment generally involves addressing the underlying carcinoid tumor and medications to alleviate symptoms.

MalaCards based summary : Carcinoid Syndrome, also known as carcinoid tumor, is related to pulmonary blastoma and carcinoid tumors, intestinal. An important gene associated with Carcinoid Syndrome is CHGA (Chromogranin A), and among its related pathways/superpathways are Neuroscience and Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways. The drugs Oxaliplatin and lanreotide have been mentioned in the context of this disorder. Affiliated tissues include lung, liver and heart, and related phenotypes are episodic abdominal pain and night sweats

MedlinePlus : 44 Carcinoid tumors are rare, slow-growing cancers. They usually start in the lining of the digestive tract or in the lungs. They grow slowly and don't produce symptoms in the early stages. As a result, the average age of people diagnosed with digestive or lung carcinoids is about 60. In later stages the tumors sometimes produce hormones that can cause carcinoid syndrome. The syndrome causes flushing of the face and upper chest, diarrhea, and trouble breathing. Surgery is the main treatment for carcinoid tumors. If they haven't spread to other parts of the body, surgery can cure the cancer.

Wikipedia : 77 Carcinoid syndrome is a paraneoplastic syndrome comprising the signs and symptoms that occur secondary... more...

Related Diseases for Carcinoid Syndrome

Diseases related to Carcinoid Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 445)
# Related Disease Score Top Affiliating Genes
1 pulmonary blastoma 32.2 CHGA SYP
2 carcinoid tumors, intestinal 31.9 CHGA ENO2 MEN1 SST SYP
3 goblet cell carcinoid 30.9 CHGA ENO2
4 serotonin syndrome 30.8 CHGA GHRH HTR3A IFNA2 MEN1 PYY
5 horseshoe kidney 30.4 CHGA ENO2 SYP
6 adenoma 30.3 IGF1 MEN1 SST
7 sclerosing hemangioma 30.1 CHGA SYP
8 pulmonary sclerosing hemangioma 30.1 CHGA SYP
9 small cell carcinoma 30.1 CALCA CHGA ENO2 SYP
10 paraganglioma 30.0 CHGA ENO2 SST SYP
11 thyroid cancer 30.0 CALCA CHGA SST VEGFA
12 glomus tumor 30.0 ENO2 SYP
13 vipoma 29.8 CHGA NTS SST
14 hyperparathyroidism 29.7 CALCA CHGA MEN1
15 multiple endocrine neoplasia 29.6 CALCA CHGA MEN1
16 primary hyperparathyroidism 29.6 CALCA CHGA MEN1
17 somatostatinoma 29.6 CALCA CHGA ENO2 SST
18 gastrinoma 29.6 CHGA MEN1 SST
19 pituitary adenoma, prolactin-secreting 29.5 IGF1 MEN1 SST
20 insulinoma 29.5 CHGA MEN1 SST
21 parathyroid adenoma 29.4 CALCA CHGA MEN1
22 acromegaly 29.4 GHRH IGF1 MEN1 SST
23 thyroid carcinoma, familial medullary 29.3 CALCA CHGA ENO2 MEN1 SST
24 ectopic cushing syndrome 29.3 MEN1 SST SYP
25 islet cell tumor 29.3 CALCA CHGA MEN1 SST
26 hemangioma 29.2 CHGA ENO2 SYP VEGFA
27 small cell cancer of the lung 29.2 CALCA CHGA ENO2 SST SYP
28 ependymoma 29.2 ENO2 MEN1 SYP
29 zollinger-ellison syndrome 29.2 CHGA GHRH MEN1 NTS SST
30 constipation 29.1 CALCA HTR3A NPY NTS PYY SST
31 von hippel-lindau syndrome 29.0 CHGA MEN1 NPY VEGFA
32 multiple endocrine neoplasia, type i 28.7 CHGA GHRH MEN1 SST SYP
33 neuroendocrine tumor 28.7 CALCA CHGA ENO2 MEN1 NTS SST
34 ewing sarcoma 28.6 CHGA ENO2 IGF1 NPY SYP VEGFA
35 gastrointestinal stromal tumor 28.6 CHGA ENO2 MEN1 SYP VEGFA
36 meningioma, familial 28.5 ENO2 MEN1 SST SYP VEGFA
37 endocrine gland cancer 28.4 CALCA CHGA MEN1 SST SYP VEGFA
38 pheochromocytoma 28.3 CALCA CHGA ENO2 MEN1 NPY SST
39 appendix carcinoid tumor 12.4
40 neurofibromatosis-pheochromocytoma-duodenal carcinoid syndrome 12.2
41 carcinoid tumor childhood 12.2
42 neuroendocrine carcinoma 11.5
43 diffuse idiopathic pulmonary neuroendocrine cell hyperplasia 11.5
44 pleuropulmonary blastoma 11.2
45 insulinomatosis and diabetes mellitus 10.5 CHGA SST
46 orbital plasma cell granuloma 10.5 IFNA2 SST
47 tsh producing pituitary tumor 10.4 GHRH SST
48 isolated growth hormone deficiency, type ib 10.4 GHRH IGF1
49 acidophil adenoma 10.4 IGF1 SST
50 neuroaxonal dystrophy 10.4 ENO2 IGF1

Graphical network of the top 20 diseases related to Carcinoid Syndrome:



Diseases related to Carcinoid Syndrome

Symptoms & Phenotypes for Carcinoid Syndrome

Human phenotypes related to Carcinoid Syndrome:

33 (show all 25)
# Description HPO Frequency HPO Source Accession
1 episodic abdominal pain 33 frequent (33%) HP:0002574
2 night sweats 33 frequent (33%) HP:0030166
3 erythematous plaque 33 frequent (33%) HP:0025474
4 small intestine carcinoid 33 frequent (33%) HP:0006722
5 intestinal carcinoid 33 frequent (33%) HP:0006723
6 protracted diarrhea 33 frequent (33%) HP:0004385
7 nausea and vomiting 33 occasional (7.5%) HP:0002017
8 asthma 33 occasional (7.5%) HP:0002099
9 tricuspid regurgitation 33 occasional (7.5%) HP:0005180
10 heart murmur 33 occasional (7.5%) HP:0030148
11 rhinorrhea 33 occasional (7.5%) HP:0031417
12 palpitations 33 occasional (7.5%) HP:0001962
13 right ventricular failure 33 occasional (7.5%) HP:0001708
14 chronic noninfectious lymphadenopathy 33 occasional (7.5%) HP:0002730
15 facial telangiectasia 33 occasional (7.5%) HP:0007380
16 increased serum serotonin 33 occasional (7.5%) HP:0003144
17 bronchospasm 33 occasional (7.5%) HP:0025428
18 abnormal b-type natriuretic peptide level 33 occasional (7.5%) HP:0031138
19 epiphora 33 occasional (7.5%) HP:0009926
20 elevated hepatic transaminase 33 occasional (7.5%) HP:0002910
21 myopathy 33 very rare (1%) HP:0003198
22 paraganglioma 33 very rare (1%) HP:0002668
23 hepatic necrosis 33 very rare (1%) HP:0002605
24 lack of bowel sounds 33 very rare (1%) HP:0030145
25 atypical pulmonary carcinoid tumor 33 very rare (1%) HP:0030446

MGI Mouse Phenotypes related to Carcinoid Syndrome:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 9.9 CHGA ENO2 GHRH HTR3A IGF1 MEN1
2 homeostasis/metabolism MP:0005376 9.65 CHGA GHRH HTR3A IGF1 MEN1 NPY
3 nervous system MP:0003631 9.4 CHGA ENO2 GHRH HTR3A IGF1 MEN1

Drugs & Therapeutics for Carcinoid Syndrome

Drugs for Carcinoid Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 239)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxaliplatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 61825-94-3 6857599 5310940 9887054 43805
2
lanreotide Approved Phase 4,Phase 3,Phase 2,Early Phase 1 108736-35-2
3
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 53123-88-9 46835353 6436030 5284616
4
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 22916-47-8 4189
5
Everolimus Approved Phase 4,Phase 3,Phase 1,Phase 2 159351-69-6 6442177 70789204
6
Rasagiline Approved Phase 4 136236-51-6 3052776
7
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 83150-76-9 6400441 383414
8
Lactitol Investigational Phase 4,Phase 1,Phase 2 585-86-4, 585-88-6 493591
9 Cola Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
11 Angiopeptin Phase 4,Phase 3,Phase 2,Early Phase 1
12 Anti-Bacterial Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
13 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
14 Anti-Infective Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
15 Antifungal Agents Phase 4,Phase 3,Phase 1,Phase 2
16 Immunologic Factors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
17 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
18 Neuroprotective Agents Phase 4
19 Monoamine Oxidase Inhibitors Phase 4
20 Protective Agents Phase 4,Phase 2,Phase 1,Not Applicable
21 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1
23 Cathartics Phase 4
24 Laxatives Phase 4
25
Levoleucovorin Approved, Investigational Phase 2, Phase 3,Phase 1,Not Applicable 68538-85-2
26
leucovorin Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 58-05-9 6006 143
27
Fluorouracil Approved Phase 2, Phase 3,Phase 1,Not Applicable 51-21-8 3385
28
Bevacizumab Approved, Investigational Phase 2, Phase 3,Phase 3 216974-75-3
29
Tranexamic Acid Approved Phase 3 1197-18-8 5526
30
Somatostatin Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 38916-34-6, 51110-01-1 53481605
31
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
32
tannic acid Approved Phase 3 1401-55-4
33
Methylene blue Approved, Investigational Phase 3 61-73-4
34
Pasireotide Approved Phase 3,Phase 2,Phase 1 396091-73-9 9941444
35
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
36
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
37
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
38
Ondansetron Approved Phase 3 99614-02-5 4595
39
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3,Not Applicable 59-30-3 6037
40 Pancreatic Polypeptide Investigational Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 59763-91-6
41 Vitamin B9 Phase 2, Phase 3,Not Applicable
42 Folate Phase 2, Phase 3,Not Applicable
43 Antimetabolites, Antineoplastic Phase 2, Phase 3,Phase 1,Not Applicable
44 Antimetabolites Phase 2, Phase 3,Phase 1,Not Applicable
45 Antineoplastic Agents, Immunological Phase 2, Phase 3,Phase 3,Phase 1
46 Angiogenesis Modulating Agents Phase 2, Phase 3,Phase 3,Phase 1
47 Angiogenesis Inhibitors Phase 2, Phase 3,Phase 3,Phase 1
48 Antifibrinolytic Agents Phase 3
49 Coagulants Phase 3
50 Hemostatics Phase 3

Interventional clinical trials:

(show top 50) (show all 212)
# Name Status NCT ID Phase Drugs
1 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
2 Somatuline Autogel Preference and Health Economy Study Completed NCT00681187 Phase 4 lanreotide (Autogel formulation)
3 Overnight Switch From Rasagiline To Safinamide Recruiting NCT03843944 Phase 4 Safinamide
4 Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study. Recruiting NCT01789281 Phase 4 Everolimus;Sandostatin LAR Depot
5 Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors Unknown status NCT00227617 Phase 2, Phase 3 5-fluorouracil;leucovorin;oxaliplatin
6 The Role of Inhalations of Tranexamic Acid in Patients With Hemoptysis Unknown status NCT01496196 Phase 3 tranexamic acid;tranexamic acid
7 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors Unknown status NCT01373736 Phase 3 123I-meta-iodobenzylguanidine
8 An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome Completed NCT00774930 Phase 3 Lanreotide;Placebo
9 Telotristat Etiprate for Carcinoid Syndrome Therapy Completed NCT02063659 Phase 3 Telotristat etiprate;Placebo
10 TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome) Completed NCT01677910 Phase 3 Telotristat etiprate;Placebo-matching telotristat etiprate
11 Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms Completed NCT02026063 Phase 3 Telotristat etiprate tablets (250 mg)
12 Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor Completed NCT00412061 Phase 3 Octreotide;Placebo;Everolimus
13 Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD) Completed NCT01626378 Phase 3 TRx0237;Placebo
14 Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease Completed NCT00690430 Phase 3 Pasireotide;Octreotide
15 Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors Completed NCT00442533 Phase 2, Phase 3 Indium-111 pentetreotide
16 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
17 Ondansetron With or Without Dexamethasone to Prevent Vomiting in Patients Receiving Radiation Therapy to the Upper Abdomen Completed NCT00016380 Phase 3 dexamethasone;ondansetron
18 Cabozantinib S-malate in Treating Patients With Neuroendocrine Tumors Previously Treated With Everolimus That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery Recruiting NCT03375320 Phase 3 Cabozantinib S-malate
19 Ga-68-DOTATOC -PET in the Management of Pituitary Tumours Recruiting NCT02419664 Phase 3
20 A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours Active, not recruiting NCT01578239 Phase 3 Octreotide LAR;177Lu-DOTA0-Tyr3-Octreotate
21 Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor Active, not recruiting NCT00569127 Phase 3 Octreotide Acetate
22 Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome Terminated NCT00092287 Phase 3 lanreotide Autogel (somatostatin analogue);Sandostatin long acting release (LAR) Depot (somatostatin analogue)
23 Effect of Oral 5-HTP Intake on Urinary 5-HIAA Excretion Terminated NCT00227136 Phase 3 5-Hydroxy-Tryptamine
24 Randomized Phase III of PRRT Versus Interferon Withdrawn NCT01860742 Phase 3 Interferon alpha-2b;177Lu-DOTATATE
25 A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid Tumors Unknown status NCT01731925 Phase 2 Lanreotide;Placebo (for sunitinib);Sunitinib
26 Safety and Tolerability Profile of RAD001 Daily in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor Unknown status NCT01175096 Phase 1, Phase 2 RAD001 (everolimus, Afinitor®)
27 177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms Unknown status NCT01237457 Phase 2 177Lu-DOTATATE
28 Recombinant Anti-tumor and Anti-virus Protein for Injection to Treat Advanced Neuroendocrine Tumors Unknown status NCT02455596 Phase 2 Recombinant anti-tumor and anti-virus protein for injection (Novaferon)
29 68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors Unknown status NCT02038738 Phase 1, Phase 2 68Ga-DOTATATE will be given in tracer doses and injected intravenously to image tumors by Positron Emission Tomography.
30 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
31 Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Completed NCT01104415 Phase 2 Telotristat etiprate
32 Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy Completed NCT00853047 Phase 2 Telotristat etiprate;Octreotide LAR Depot;Placebo
33 Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors Completed NCT00088595 Phase 2 Pasireotide (SOM230)
34 Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs) Completed NCT02299089 Phase 2 octreotide FluidCrystal® injection depot
35 Fluorouracil Plus Interferon Alfa in Treating Patients With Advanced Metastatic Carcinoid Tumors Completed NCT00002470 Phase 2 fluorouracil
36 Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors Completed NCT00055809 Phase 2
37 Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery Completed NCT00416767 Phase 2 fluorouracil;irinotecan hydrochloride;leucovorin calcium
38 Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors Completed NCT00602082 Phase 2 capecitabine;cisplatin;streptozocin
39 AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors Completed NCT00427349 Phase 2 AMG 706;octreotide
40 Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma Completed NCT00093782 Phase 2 temsirolimus
41 PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00017199 Phase 2 bortezomib
42 Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00027638 Phase 2 thalidomide
43 Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00131911 Phase 2 sorafenib tosylate
44 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
45 Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00075439 Phase 2 gefitinib
46 Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer Completed NCT00454363 Phase 2 Pazopanib Hydrochloride
47 Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer Completed NCT00019474 Phase 2 fluorouracil;hydroxyurea
48 Endoscopic Placement of Metal Stent in Patients With Cancer-Related Bowel Obstruction Completed NCT00004911 Phase 1, Phase 2
49 Endoscopic Placement of Metal Stents in Treating Patients With Cancer- Related Duodenal Obstruction Completed NCT00004910 Phase 1, Phase 2
50 Combination Chemotherapy in Treating Patients With Stage III Ovarian Epithelial Cancer or Gastrointestinal Cancer Completed NCT00005049 Phase 2 carboplatin;cisplatin;floxuridine

Search NIH Clinical Center for Carcinoid Syndrome

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Genetic Tests for Carcinoid Syndrome

Genetic tests related to Carcinoid Syndrome:

# Genetic test Affiliating Genes
1 Carcinoid Tumor 30

Anatomical Context for Carcinoid Syndrome

MalaCards organs/tissues related to Carcinoid Syndrome:

42
Lung, Liver, Heart, Breast, Appendix, Ovary, Skin

Publications for Carcinoid Syndrome

Articles related to Carcinoid Syndrome:

(show top 50) (show all 2106)
# Title Authors Year
1
Management of carcinoid syndrome: a systematic review and meta-analysis. ( 30608900 )
2019
2
Long-Term Safety Experience with Telotristat Ethyl Across Five Clinical Studies in Patients with Carcinoid Syndrome. ( 30651397 )
2019
3
Generalized Cytokine Increase in the Setting of a Multisystem Clinical Disorder and Carcinoid Syndrome Associated with a Novel NLRP12 Variant. ( 30788684 )
2019
4
Sclerosing pneumocytoma mixed with a typical carcinoid tumor: A case report and review of literature. ( 30702609 )
2019
5
Β-Adrenergic agonist administration is not associated with secondary carcinoid crisis in patients with carcinoid tumor. ( 30635207 )
2019
6
Case report: Ectopic ACTH secretion due to a metastatic atypical lung carcinoid tumor. From diagnosis to treatment. ( 30739712 )
2019
7
A rare testicular tumor: primary carcinoid tumor. ( 30799770 )
2019
8
A case of pseudocystic liver metastases from an atypical lung carcinoid tumor. ( 30891110 )
2019
9
Cost-effectiveness analysis of telotristat ethyl for treatment of carcinoid syndrome diarrhea inadequately controlled with somatostatin analogs. ( 28959913 )
2018
10
Developments in the treatment of carcinoid syndrome - impact of telotristat. ( 29503551 )
2018
11
Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial. ( 29330194 )
2018
12
LANREOTIDE THERAPY IN CARCINOID SYNDROME: PROSPECTIVE ANALYSIS OF PATIENT-REPORTED SYMPTOMS IN PATIENTS RESPONSIVE TO PRIOR OCTREOTIDE THERAPY AND PATIENTS NAA8VE TO SOMATOSTATIN ANALOGUE THERAPY IN THE ELECT PHASE 3 STUDY. ( 29547049 )
2018
13
Carcinoid-syndrome: recent advances, current status and controversies. ( 29120923 )
2018
14
Telotristat Ethyl for Patients With Carcinoid Syndrome Associated With Chest Pain and Hypertension. ( 29232344 )
2018
15
A case of a primary lung cancer comprised of adenocarcinoma and atypical carcinoid tumor with both components harboring BRAF p.V600E mutation. ( 29248665 )
2018
16
The management of refractory carcinoid syndrome: challenges and opportunities ahead. ( 29039712 )
2018
17
Diagnostic Dilemma: Carcinoid Syndrome. ( 29906424 )
2018
18
Changes in Weight Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome. ( 29724499 )
2018
19
Telotristat ethyl: a novel agent for the therapy of carcinoid syndrome diarrhea. ( 29350062 )
2018
20
Telotristat Ethyl: A Review in Carcinoid Syndrome Diarrhoea. ( 29931594 )
2018
21
A Case of Carcinoid Syndrome Due to Malignant Metastatic Carcinoid Tumor with Carcinoid Heart Disease Involving Four Cardiac Valves. ( 29527003 )
2018
22
Distinct Imaging Characteristics of Different Metastases From Primary Prostate Adenocarcinoma and Rectal Carcinoid Tumor on 18F-Fluciclovine and 68Ga-DOTATATE PET/CT. ( 30371597 )
2018
23
Grade 3 Neuroendocrine Tumor (G3 NET) in a Background of Multiple Serotonin Cell Neoplasms of the Ileum Associated with Carcinoid Syndrome and Aggressive Behavior. ( 30076568 )
2018
24
Telotristat ethyl for the treatment of carcinoid syndrome diarrhea not controlled by somatostatin analogues. ( 30090879 )
2018
25
Economic analysis of inadequate symptom control in carcinoid syndrome in the United States. ( 30095284 )
2018
26
New Treatments for the Carcinoid Syndrome. ( 30098716 )
2018
27
Carcinoid syndrome: update on the pathophysiology and treatment. ( 30133565 )
2018
28
In Reply: Telotristat Ethyl for Patients With Carcinoid Syndrome Associated With Chest Pain and Hypertension. ( 30153219 )
2018
29
Image Gallery: Flush in carcinoid syndrome. ( 30156289 )
2018
30
Oral Ondansetron Offers Effective Antidiarrheal Activity for Carcinoid Syndrome Refractory to Somatostatin Analogs. ( 30171068 )
2018
31
Patent foramen ovale with an enormous right-to-left shunt: unusual reversible cause of hypoxia in carcinoid syndrome. ( 30184060 )
2018
32
Primary Mesenteric Carcinoid Tumor Presenting with Carcinoid Syndrome. ( 30186091 )
2018
33
Cases in a series of carcinoid syndrome and carcinoid heart disease. ( 30204224 )
2018
34
An update of lanreotide acetate for treatment of adults with carcinoid syndrome. ( 30209440 )
2018
35
Intraoperative carcinoid syndrome during small-bowel neuroendocrine tumour surgery. ( 30352418 )
2018
36
Influence of carcinoid syndrome on the clinical characteristics and outcomes of patients with gastroenteropancreatic neuroendocrine tumors undergoing operative resection. ( 30377003 )
2018
37
Real-world treatment patterns, resource use and costs of treating uncontrolled carcinoid syndrome and carcinoid heart disease: a retrospective Swedish study. ( 30449217 )
2018
38
Impact of carcinoid syndrome symptoms and long-term use of somatostatin analogs on quality of life in patients with carcinoid syndrome: A survey study. ( 30461659 )
2018
39
Relationship Between Symptoms and Health-Related Quality-of-Life Benefits in Patients With Carcinoid Syndrome: Post Hoc Analyses From TELESTAR. ( 30477789 )
2018
40
Resection of a mature cystic teratoma of the liver harboring a carcinoid tumor. ( 30397434 )
2018
41
Unusual cardiac paraganglioma mimicking an atypical carcinoid tumor of the lung. ( 29600100 )
2018
42
Metastatic medullary thyroid carcinoma or calcitonin-secreting carcinoid tumor of lung? A diagnostic dilemma in a patient with lung mass and thyroid nodule. ( 29124912 )
2018
43
Primary Pulmonary Carcinoid Tumor: A Long-term Single Institution Experience. ( 26270444 )
2018
44
Rectal Carcinoid Tumor With Liver Metastases Treated by Local Excision and Orthotopic Liver Transplant With Long-term Follow-up. ( 28350289 )
2018
45
Kidney carcinoid tumor: Histological, immunohistochemical and ultrastructural features. ( 29192809 )
2018
46
Case report: Ectopic Cushing's syndrome in a young male with hidden lung carcinoid tumor. ( 29202350 )
2018
47
Clinicopathological indicators of survival among patients with pulmonary carcinoid tumor. ( 29463166 )
2018
48
Subcutaneous metastasis of a pulmonary carcinoid tumor: A case report. ( 29480829 )
2018
49
Endobronchial Tuberculosis Simulating Carcinoid Tumor. ( 29482702 )
2018
50
Successful Salvage Chemotherapy with Streptozocin in a Patient with Mediastinal Atypical Carcinoid Tumor Who Had Relapsed after Various Prior Therapies. ( 29515410 )
2018

Variations for Carcinoid Syndrome

Expression for Carcinoid Syndrome

Search GEO for disease gene expression data for Carcinoid Syndrome.

Pathways for Carcinoid Syndrome

Pathways related to Carcinoid Syndrome according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.99 CALCA ENO2 NPY SYP
2 11.71 HTR3A SST VEGFA
3 11.13 ENO2 IGF1 VEGFA
4 10.7 IGF1 SYP VEGFA
5 10.62 NPY PYY

GO Terms for Carcinoid Syndrome

Cellular components related to Carcinoid Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.65 CALCA CHGA GHRH IFNA2 IGF1 NPY
2 neuron projection GO:0043005 9.62 CALCA GHRH HTR3A SYP
3 neuronal cell body GO:0043025 9.56 CALCA ENO2 HTR3A SST
4 terminal bouton GO:0043195 9.33 CALCA GHRH SYP
5 extracellular space GO:0005615 9.32 CALCA CHGA ENO2 GHRH IFNA2 IGF1

Biological processes related to Carcinoid Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor signaling pathway GO:0007186 9.88 CALCA GHRH NPY NTS PYY SST
2 cell-cell signaling GO:0007267 9.62 CALCA GHRH IFNA2 SST
3 neuropeptide signaling pathway GO:0007218 9.61 CALCA NPY PYY
4 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.54 IFNA2 IGF1 VEGFA
5 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.46 GHRH IGF1
6 regulation of blood pressure GO:0008217 9.43 CALCA CHGA NPY
7 response to heat GO:0009408 9.33 CALCA IGF1 SST
8 regulation of signaling receptor activity GO:0010469 9.28 CALCA GHRH IFNA2 IGF1 NPY NTS
9 feeding behavior GO:0007631 9.13 CALCA NPY PYY

Molecular functions related to Carcinoid Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuropeptide hormone activity GO:0005184 9.26 GHRH NPY NTS PYY
2 hormone activity GO:0005179 9.1 CALCA GHRH IGF1 NPY PYY SST

Sources for Carcinoid Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....